Back to results
US 12,319,724 B2Granted
IL2 agonists and methods of use thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to IL2 agonists with improved therapeutic profiles.
Claims13
A heterodimer comprising:
- (a) a first polypeptide chain comprising, in N-to C-terminal orientation:
- (i) a peptide-MHC (pMHC) complex comprising a class I α heavy chain human HLA-A2 sequence and a peptide, the peptide comprising the amino acid sequence of HPV 16E7 (11-19), HPV 16E7 (82-90), CMV pp65 (495-503), NY-ESO-1 (157-165) mutant C165V, WT-1 (126-134), or Tyrosinase (369-377);
- and
- (ii) a first Fc domain;
- and
- (b) a second polypeptide chain comprising, in N- to C-terminal orientation:
- (i) an IL2 domain comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:2 and the amino acid substitutions H16A and F42A as compared to SEQ ID NO:2;
- and
- (ii) a second Fc domain capable of heterodimerizing with the first Fc domain.
6 more elements
Dependencies are inferred from the claim text.